The major function of the Administrative Core is to provide oversight of the of the P01 and to insure that theresources available to members of the P01 are efficiently utilized to advance our understanding of ProstateCancer and to identify new approaches for detection, evaluation and treatment of this disease/The role thatDr. Cantley plays as P.I. of the grant and as head of the Administrative Core is to insure that the ProjectLeaders and Core Leaders interact in a collaborative way, share information and reagents in realtime, haveaccess to emerging discoveries and technologies, have access to the resources of the three scientific coresand obtain critical feedback from the Scientific Advisory Committee. Dr. Cantley, with the assistance of Ms.Stukuls, organizes meetings where the members of the P01 discuss progress and future directions,organizes meetings with the Scientific Advisory Committee, organizes a seminar series with outsidespeakers, coordinates (with Dr. Philip Kantoff) joint meetings of the Prostate Cancer P01 with the ProstateCancer SPORE and organizes local and national meetings on Prostate Cancer research. In addition, Dr.Cantley, as a member of the Executive Committee of the Dana Farber Harvard Cancer Center, periodicallyreports to the DFHCC on the progress of the P01 and the interactions between the Prostate Cancer P01 andSPORE in the mission of the Prostate Cancer Program.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
2P01CA089021-06A1
Application #
7225387
Study Section
Special Emphasis Panel (ZCA1-GRB-S (O1))
Project Start
2006-07-01
Project End
2011-06-30
Budget Start
2006-07-01
Budget End
2008-05-31
Support Year
6
Fiscal Year
2007
Total Cost
$83,537
Indirect Cost
Name
Beth Israel Deaconess Medical Center
Department
Type
DUNS #
071723621
City
Boston
State
MA
Country
United States
Zip Code
02215
Patnaik, Akash; Swanson, Kenneth D; Csizmadia, Eva et al. (2017) Cabozantinib Eradicates Advanced Murine Prostate Cancer by Activating Antitumor Innate Immunity. Cancer Discov 7:750-765
Lee, So Jin; Kim, Min Ju; Kwon, Ick Chan et al. (2016) Delivery strategies and potential targets for siRNA in major cancer types. Adv Drug Deliv Rev 104:2-15
Martin, Neil E; Gerke, Travis; Sinnott, Jennifer A et al. (2015) Measuring PI3K Activation: Clinicopathologic, Immunohistochemical, and RNA Expression Analysis in Prostate Cancer. Mol Cancer Res 13:1431-40
Selvarajah, Shamini; Pyne, Saumyadipta; Chen, Eleanor et al. (2014) High-resolution array CGH and gene expression profiling of alveolar soft part sarcoma. Clin Cancer Res 20:1521-30
González-Billalabeitia, Enrique; Seitzer, Nina; Song, Su Jung et al. (2014) Vulnerabilities of PTEN-TP53-deficient prostate cancers to compound PARP-PI3K inhibition. Cancer Discov 4:896-904
Flavin, Richard; Pettersson, Andreas; Hendrickson, Whitney K et al. (2014) SPINK1 protein expression and prostate cancer progression. Clin Cancer Res 20:4904-11
Liu, Z; Zanata, S M; Kim, J et al. (2013) The ubiquitin-specific protease USP2a prevents endocytosis-mediated EGFR degradation. Oncogene 32:1660-9
Ittmann, Michael; Huang, Jiaoti; Radaelli, Enrico et al. (2013) Animal models of human prostate cancer: the consensus report of the New York meeting of the Mouse Models of Human Cancers Consortium Prostate Pathology Committee. Cancer Res 73:2718-36
Chen, Sen; Jiang, Xinnong; Gewinner, Christina A et al. (2013) Tyrosine kinase BMX phosphorylates phosphotyrosine-primed motif mediating the activation of multiple receptor tyrosine kinases. Sci Signal 6:ra40
Jia, Shidong; Gao, Xueliang; Lee, Sang Hyun et al. (2013) Opposing effects of androgen deprivation and targeted therapy on prostate cancer prevention. Cancer Discov 3:44-51

Showing the most recent 10 out of 94 publications